tiprankstipranks
Trending News
More News >
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
US Market

Reviva Pharmaceuticals Holdings (RVPH) Stock Forecast & Price Target

Compare
330 Followers
See the Price Targets and Ratings of:

RVPH Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Reviva
Pharmaceuticals Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVPH Stock 12 Month Forecast

Average Price Target

$9.00
▲(922.73%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Reviva Pharmaceuticals Holdings in the last 3 months. The average price target is $9.00 with a high forecast of $16.00 and a low forecast of $3.00. The average price target represents a 922.73% change from the last price of $0.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","-1":"-$1","3.5":"$3.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,2.043076923076923,3.206153846153846,4.36923076923077,5.532307692307692,6.695384615384616,7.858461538461539,9.021538461538462,10.184615384615386,11.34769230769231,12.510769230769233,13.673846153846155,14.836923076923078,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,1.5046153846153847,2.129230769230769,2.753846153846154,3.378461538461538,4.0030769230769225,4.627692307692308,5.252307692307692,5.8769230769230765,6.501538461538461,7.126153846153845,7.75076923076923,8.375384615384615,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,1.043076923076923,1.2061538461538461,1.3692307692307693,1.5323076923076924,1.6953846153846155,1.8584615384615386,2.0215384615384617,2.184615384615385,2.347692307692308,2.510769230769231,2.673846153846154,2.836923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.81,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$9.00Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on RVPH
Bruce JacksonBenchmark Co.
Benchmark Co.
$14
Buy
1490.91%
Upside
Reiterated
05/23/25
Analysts' Top Healthcare Picks: Delcath Systems (DCTH), Reviva Pharmaceuticals Holdings (RVPH)
Roth MKM
$7
Buy
695.45%
Upside
Reiterated
05/20/25
Roth MKM Sticks to Its Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)
D. Boral Capital Analyst forecast on RVPH
Jason KolbertD. Boral Capital
D. Boral Capital
$8$3
Buy
240.91%
Upside
Reiterated
05/20/25
Reviva Pharmaceuticals price target lowered to $3 from $8 at D. Boral CapitalReviva Pharmaceuticals price target lowered to $3 from $8 at D. Boral Capital
Maxim Group Analyst forecast on RVPH
Jason McCarthyMaxim Group
Maxim Group
$5
Buy
468.18%
Upside
Reiterated
05/16/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX) and Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)
Alliance Global Partners Analyst forecast on RVPH
James MolloyAlliance Global Partners
Alliance Global Partners
$16
Buy
1718.18%
Upside
Reiterated
04/01/25
Reiterating our Buy rating and $16 price target based on a sum-of-the-parts.
H.C. Wainwright Analyst forecast on RVPH
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$11
Buy
1150.00%
Upside
Reiterated
01/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on RVPH
Bruce JacksonBenchmark Co.
Benchmark Co.
$14
Buy
1490.91%
Upside
Reiterated
05/23/25
Analysts' Top Healthcare Picks: Delcath Systems (DCTH), Reviva Pharmaceuticals Holdings (RVPH)
Roth MKM
$7
Buy
695.45%
Upside
Reiterated
05/20/25
Roth MKM Sticks to Its Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)
D. Boral Capital Analyst forecast on RVPH
Jason KolbertD. Boral Capital
D. Boral Capital
$8$3
Buy
240.91%
Upside
Reiterated
05/20/25
Reviva Pharmaceuticals price target lowered to $3 from $8 at D. Boral CapitalReviva Pharmaceuticals price target lowered to $3 from $8 at D. Boral Capital
Maxim Group Analyst forecast on RVPH
Jason McCarthyMaxim Group
Maxim Group
$5
Buy
468.18%
Upside
Reiterated
05/16/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX) and Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)
Alliance Global Partners Analyst forecast on RVPH
James MolloyAlliance Global Partners
Alliance Global Partners
$16
Buy
1718.18%
Upside
Reiterated
04/01/25
Reiterating our Buy rating and $16 price target based on a sum-of-the-parts.
H.C. Wainwright Analyst forecast on RVPH
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$11
Buy
1150.00%
Upside
Reiterated
01/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Reviva Pharmaceuticals Holdings

1 Month
xxx
Success Rate
4/8 ratings generated profit
50%
Average Return
-2.51%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -2.51% per trade.
3 Months
xxx
Success Rate
1/8 ratings generated profit
13%
Average Return
-21.15%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 12.50% of your transactions generating a profit, with an average return of -21.15% per trade.
1 Year
Jason McCarthyMaxim Group
Success Rate
1/8 ratings generated profit
13%
Average Return
-55.80%
reiterated a buy rating 2 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -55.80% per trade.
2 Years
xxx
Success Rate
1/8 ratings generated profit
13%
Average Return
-57.10%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -57.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVPH Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Apr 25
May 25
Jun 25
Strong Buy
2
4
7
11
9
Buy
0
0
1
1
1
Hold
3
2
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
9
12
10
In the current month, RVPH has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RVPH average Analyst price target in the past 3 months is 9.00.
Each month's total comprises the sum of three months' worth of ratings.

RVPH Financial Forecast

RVPH Earnings Forecast

Next quarter’s earnings estimate for RVPH is -$0.13 with a range of -$0.18 to -$0.08. The previous quarter’s EPS was -$0.13. RVPH beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RVPH has Outperformed its overall industry.
Next quarter’s earnings estimate for RVPH is -$0.13 with a range of -$0.18 to -$0.08. The previous quarter’s EPS was -$0.13. RVPH beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RVPH has Outperformed its overall industry.
No data currently available

RVPH Sales Forecast

Next quarter’s sales forecast for RVPH is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. RVPH beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year RVPH has Preformed in-line its overall industry.
Next quarter’s sales forecast for RVPH is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. RVPH beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year RVPH has Preformed in-line its overall industry.

RVPH Stock Forecast FAQ

What is RVPH’s average 12-month price target, according to analysts?
Based on analyst ratings, Reviva Pharmaceuticals Holdings’s 12-month average price target is 9.00.
    What is RVPH’s upside potential, based on the analysts’ average price target?
    Reviva Pharmaceuticals Holdings has 922.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RVPH a Buy, Sell or Hold?
          Reviva Pharmaceuticals Holdings has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Reviva Pharmaceuticals Holdings’s price target?
            The average price target for Reviva Pharmaceuticals Holdings is 9.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $3.00. The average price target represents 922.73% Increase from the current price of $0.88.
              What do analysts say about Reviva Pharmaceuticals Holdings?
              Reviva Pharmaceuticals Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of RVPH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis